Education
About Us
Working with TipRanks
Follow Us
FFTY - ETF AI Analysis
Top Page
Innovator IBD 50 ETF (FFTY)
Rating:72Outperform
Price Target:―
Positive Factors
Strong Year-to-Date Performance
The ETF has delivered solid year-to-date returns, indicating strong momentum in its holdings.
Technology Sector Leadership
With significant exposure to the technology sector, the fund benefits from the strong performance of innovative companies.
Top Holdings Driving Growth
Several top holdings, such as Robinhood and Stoke Therapeutics, have shown strong year-to-date gains, contributing positively to the fund.
Negative Factors
High Expense Ratio
The ETF charges a relatively high expense ratio compared to many other funds, which can eat into investor returns over time.
Over-Concentration in U.S. Market
The fund is heavily focused on U.S. companies, limiting diversification and increasing vulnerability to domestic market risks.
Underperforming Holding
SoundHound AI, one of the top holdings, has lagged in performance, which could weigh on overall returns.
FFTY vs. SPDR S&P 500 ETF (SPY)
AUM87.94M
RegionNorth America
Expense Ratio0.80%
Beta1.47
IssuerInnovator
Inception DateApr 09, 2015
Dividend Yield0.75%
Asset ClassEquity
Index TrackedIBD 50 TR
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume108,772
30 Day Avg. Volume202,400
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
39.48Price Target Upside― Downside
Rating ConsensusStrong Buy
Number of Analyst Covering50
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
FFTY Summary
The Innovator IBD 50 ETF (FFTY) is an investment fund that tracks the IBD 50 Index, which focuses on 50 high-performing growth stocks. It includes companies with strong earnings and sales growth, such as Palantir Technologies and Micron. This ETF is heavily weighted toward technology and healthcare sectors, making it a good choice for investors looking to capitalize on innovative and fast-growing industries. However, since it focuses on growth stocks, its value can rise and fall quickly with market trends, making it more volatile than broader ETFs.
How much will it cost me?The Innovator IBD 50 ETF (FFTY) has an expense ratio of 0.8%, which means you’ll pay $8 per year for every $1,000 invested. This is higher than average because it’s actively managed, focusing on selecting top-performing growth stocks rather than passively tracking a broad index.
What would affect this ETF?The Innovator IBD 50 ETF (FFTY), with its focus on growth stocks and heavy exposure to technology and healthcare sectors, could benefit from advancements in innovation, favorable economic conditions, and increased investor interest in high-growth industries. However, it may face challenges from rising interest rates, regulatory changes, or economic slowdowns, which could negatively impact smaller-cap stocks and growth-focused companies. Its U.S.-centric portfolio also makes it sensitive to domestic market trends and policies.
FFTY Top 10 Holdings
The Innovator IBD 50 ETF is leaning heavily into growth sectors like technology and healthcare, with names like Micron and Celestica providing steady tailwinds thanks to strong earnings and strategic investments in AI and capacity expansion. However, not all holdings are pulling their weight—Credo Technology and Sterling Infrastructure are lagging, with valuation concerns and bearish technical trends tempering their contributions. The fund’s U.S.-centric portfolio is a dynamic mix of rising stars and a few underperformers, but its focus on high-growth industries keeps it positioned for potential upside.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Celestica | 3.89% | $3.42M | $40.43B | 208.97% | 76 Outperform | |
| Micron | 3.77% | $3.31M | $290.86B | 135.26% | 77 Outperform | |
| Comfort Systems | 3.69% | $3.24M | $36.15B | 109.36% | 77 Outperform | |
| Stoke Therapeutics | 3.65% | $3.21M | $1.89B | 168.57% | 70 Outperform | |
| IAMGOLD | 3.62% | $3.18M | $9.16B | 196.63% | 73 Outperform | |
| AnaptysBio | 3.57% | $3.14M | $1.27B | 188.26% | 49 Neutral | |
| Travere Therapeutics | 3.43% | $3.02M | $3.13B | 101.10% | 56 Neutral | |
| Arcutis Biotherapeutics | 3.36% | $2.95M | $3.61B | 140.57% | 60 Neutral | |
| Gold Fields | 3.23% | $2.84M | $38.81B | 202.22% | 79 Outperform | |
| Rambus | 3.16% | $2.78M | $11.41B | 64.14% | 78 Outperform |
FFTY Technical Analysis
Negative
―
Price Trends
37.23
Negative
36.29
Negative
32.63
Positive
Market Momentum
-0.43
Negative
42.62
Neutral
60.70
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For FFTY, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 34.77, equal to the 50-day MA of 37.23, and equal to the 200-day MA of 32.63, indicating a neutral trend. The MACD of -0.43 indicates Negative momentum. The RSI at 42.62 is Neutral, neither overbought nor oversold. The STOCH value of 60.70 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FFTY.
FFTY Peer Comparison
Comparison Results
Performance Comparison
FFTY
Innovator IBD 50 ETF
34.62
3.65
11.79%
TMFE
Motley Fool Capital Efficiency 100 Index ETF
―
―
―
BAMD
Brookstone Dividend Stock ETF
―
―
―
STNC
Stance Equity ESG Large Cap Core ETF
―
―
―
RFDA
RiverFront Dynamic US Dividend Advantage ETF
―
―
―
STOX
Horizon Core Equity ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents